Bannerbild German Brest Group

GBG Research at ESMO

15.10.2018

Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.

Clinical trials

GeparSepto (GBG 69, NCT 01583426): results of follow-up

#188PD: Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)

  • Session: Poster Discussion session - Breast cancer, early stage; 20.10.2018, 15:00 - 16:15; Hall A1 - Room 15 (poster discussion)
  • First author: M. Untch; HELIOS Klinikum Berlin-Buch, Berlin; Germany


MALE (GBG 54, NCT01638247): final analysis

#273PD: Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients

  • Session: Poster Discussion session - Breast cancer, metastatic; 21.10.2018; 09:15 - 10:30; ICM - Room 1(poster discussion)
  • First author: M Reinisch; Kliniken Essen-Mitte, Essen, Germany


AMICA (GBG 97, NCT03555877): trial in progress

#364TiP: Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: a phase II trial (AMICA) GBG 97

  • Session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care; 22.10.2018; 12:45 - 13:45; Hall A3 - Poster Area Networking Hub (TIP poster)
  • First author: T. Decker; Hämatologie, Onkologie, Ravensburg, Germany


PATINA (GBG 94, AFT-38, NCT02947685): trial in progress

#369TiP: PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy (ET) vs. Anti-HER2 Therapy + ET after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (MBC)

  • Session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care; 22.10.2018; 12:45 - 13:45; Hall A3 - Poster Area Networking Hub (TIP poster)
  • First author: S. Loibl, German Breast Group, Neu-Isenburg; Germany


Translational research

Results using samples obtained from patients with early breast cancer enrolled in PREPARE and TECHNO trials

#227P: Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) Subtypes

  • Session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care; 22.10.2018; 12:45 - 13:45; Hall A3 - Poster Area Networking Hub (poster)
  • First author: P.A. Fasching; Department of Gyn/Ob, Universitätsklinik Erlangen, Germany


#168P: Validation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC)

  • Session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research; 20.10.2018; 12:30 - 13:30; Hall A3 - Poster Area Networking Hub (poster)
  •  First author: P.A. Fasching; Department of Gyn/Ob, Universitätsklinik Erlangen, Germany


Results using samples obtained from patients with TNBC enrolled in GeparOcto trial (GBG 84, NCT02125344)

#243P: Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study

  • Session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care; 22.10.2018; 12:45 - 13:45; Hall A3 - Poster Area Networking Hub (poster)
  • First author: E. Pohl-Rescigno; Center for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany


More Information about ESMO 2018 is available on this website.

News

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd